Examples of 'pirfenidone' in a sentence
Meaning of "pirfenidone"
pirfenidone (verb) - is a type of action or behavior related to the use or application of the medication called pirfenidone, which is used for the treatment of idiopathic pulmonary fibrosis
Show more definitions
- An experimental drug for the treatment of idiopathic pulmonary fibrosis.
How to use "pirfenidone" in a sentence
Basic
Advanced
pirfenidone
Improving administration of pirfenidone by advising or cautioning patient.
Pirfenidone and pirfenidone analogs are described above.
The synthesis of pirfenidone has been worked out.
No ethyl acetate or butanol was detected in the pirfenidone.
The bioavailability of pirfenidone has not been determined in humans.
Pirfenidone therapy avoiding fluvoxamine.
Method of providing pirfenidone therapy to a patient.
Pirfenidone treatment for patients with atypical liver function.
Subjects may not be on both pirfenidone and nintedanib.
Modifying pirfenidone treatment for patients with fibrosis.
The active substance is pirfenidone.
Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
Esbriet is a medicine that contains the active substance pirfenidone.
The pirfenidone is taken with food.
Concomitant treatment with pirfenidone.
See also
The mechanism of action of pirfenidone has not been fully established.
Pirfenidone was dissolved in hot agar.
Selecting an alternative drug to administer concurrently with pirfenidone therapy.
It is unknown whether pirfenidone or its metabolites are excreted in human milk.
The invention further provides a starter pack comprising pirfenidone.
Pirfenidone alone has no effect.
Methods of administering pirfenidone therapy.
Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis.
Also described are derivatives of pirfenidone.
Pirfenidone should be taken with food to help decrease nausea or dizziness.
Methods of reducing adverse events associated with pirfenidone therapy.
The pirfenidone can be precipitated to form a more purified form of pirfenidone.
The uses are for administering a therapeutically acceptable amount of pirfenidone.
The pirfenidone can be administered any time of day with food.
A composition as described herein may further include pirfenidone or a pirfenidone analog.
Pirfenidone demonstrates a consistent antifibrotic effect in several animal models of pulmonary fibrosis.
Such a patient is a patient who would benefit from pirfenidone administration.
Pirfenidone should be used with caution in patients with moderate renal impairment.
The resulting crystallized pirfenidone can then be collected vía filtration and dried.
Lung function among albino sufferers improved slightly in a previous pirfenidone study.
The pirfenidone can additionally or alternatively be crystallized to form a more purified pirfenidone.
The uses disclosed herein include administering pirfenidone to a patient with food.
The resulting solid pirfenidone precipitate can be collected vía filtration and dried.
No dose adjustment is required in patients with mild renal impairment who are receiving pirfenidone.
Certain medications like pirfenidone or nintedanib may slow the progression of the disease.
Patients must be advised to abstain from cigarette smoking while on therapy with pirfenidone.
Avoiding concomitant use of pirfenidone and ciprofloxacin at equivalent dosing by other routes is contemplated.
Nor did the researchers find any biomarkers that could predict benefit from pirfenidone.
Pirfenidone is administered to the patient in accordance with the treatment regimes as described above.
The disclosure further contemplates such use of pirfenidone in one or more unit dosage forms.
Drugs such as pirfenidone are currently being tested in IPF patients.
A pharmaceutical composition preferably contains a total amount of pirfenidone sufficient to achieve an intended therapeutic effect.
Avoiding or discontinuing administration of a CYP inducer to avoid adverse drug interactions with pirfenidone.
Other disorders that would benefit from therapy with pirfenidone include inflammatory disorders or autoimmune disorders.
Pirfenidone demonstrated a favorable safety profile and was generally well tolerated in both CAPACITY studies.
